RNAC Stock Price, Chart, Stats & News
Cartesian Therapeutics Inc. (RNAC) does not currently pay a dividend.
RNAC chart
Fundamentals
Gross margin | -357.53% |
Operating margin | -3099.93% |
Pretax margin | -4987.31% |
Net margin | -4658.63% |
Effective tax rate | 6.59% |
ROA | -43.96% |
ROE | 279.62% |
D/E | -0.10x |
Interest coverage ratio | – |
RNAC valuation
P/E | – |
P/S | 55.44x |
P/B | -1.20x |
P/CF | -2.05x |
P/FCF | -1.95x |
P/OCF | -2.05x |
PEG | 0.01x |
EV multiple | -4.35x |
About
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma.
Similar securities
Based on sector and market capitalization
